Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Sean N Avedissian *Antiviral Pharmacology Laboratory, College of Pharmacy, University of Nebraska Medical Center, 986145 Nebraska Medical Center, Omaha, NE, 68198-6145, USA. Sean.avedissian@unmc.edu.ORCID 0000-0002-0935-6455
Johid R Malik *Antiviral Pharmacology Laboratory, College of Pharmacy, University of Nebraska Medical Center, 986145 Nebraska Medical Center, Omaha, NE, 68198-6145, USA.ORCID 0000-0001-5999-9187
Anthony T PodanyAntiviral Pharmacology Laboratory, College of Pharmacy, University of Nebraska Medical Center, 986145 Nebraska Medical Center, Omaha, NE, 68198-6145, USA.ORCID 0000-0002-8371-0379
Michael NeelyDepartment of Pediatrics, Division of Infectious Diseases, University of Southern California, Children's Hospital Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-1675-8276
Nathaniel J RhodesDepartment of Pharmacy Practice, Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, USA.ORCID 0000-0002-0018-5434
Kimberly K ScarsiAntiviral Pharmacology Laboratory, College of Pharmacy, University of Nebraska Medical Center, 986145 Nebraska Medical Center, Omaha, NE, 68198-6145, USA.ORCID 0000-0001-9406-693X
Marc H ScheetzDepartment of Pharmacy Practice, Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, USA.ORCID 0000-0002-1091-6130
Michael J DuryeeDivision of Rheumatology, Department of Pharmacology & Experimental Neurosciences Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.ORCID 0000-0001-9104-2238
Ukamaka O ModebeluAntiviral Pharmacology Laboratory, College of Pharmacy, University of Nebraska Medical Center, 986145 Nebraska Medical Center, Omaha, NE, 68198-6145, USA.ORCID 0009-0009-3538-3033
Timothy M MykrisAntiviral Pharmacology Laboratory, College of Pharmacy, University of Nebraska Medical Center, 986145 Nebraska Medical Center, Omaha, NE, 68198-6145, USA.ORCID 0000-0002-0959-6563
Lee C WinchesterAntiviral Pharmacology Laboratory, College of Pharmacy, University of Nebraska Medical Center, 986145 Nebraska Medical Center, Omaha, NE, 68198-6145, USA.ORCID 0000-0002-6118-024X
Siddappa N ByrareddyDepartment of Pharmacology & Experimental Neurosciences, University of Nebraska Medical Center, Omaha, NE, USA.ORCID 0000-0002-6889-4640
Courtney V FletcherAntiviral Pharmacology Laboratory, College of Pharmacy, University of Nebraska Medical Center, 986145 Nebraska Medical Center, Omaha, NE, 68198-6145, USA. cfletcher@unmc.edu.ORCID 0000-0002-3703-7849
Funding
Investigations of antiretroviral therapy penetration in cerebrospinal fluidK23MH125734 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI AVEDISSIAN, SEAN · 2021 to 2025
$862k
NIMH NIH HHS K23 MH125734
6 · The paper itself
Abstract
Three years after SARS-CoV-2 emerged as a global infectious threat, the virus has become endemic. The neurological complications such as depression, anxiety, and other CNS complications after COVID-19 disease are increasing. The brain, and CSF have been shown as viral reservoirs for SARS-CoV-2, yielding a potential hypothesis for CNS effects. Thus, we investigated the CNS pharmacology of orally dosed nirmatrelvir/ritonavir (NMR/RTV). Using both an in vitro and an in vivo rodent model, we investigated CNS penetration and potential pharmacodynamic activity of NMR. Through pharmacokinetic modeling, we estimated the median CSF penetration of NMR to be low at 18.11% of plasma with very low accumulation in rodent brain tissue. Based on the multiples of the 90% maximal effective concentration (EC
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
In-vitro and in-vivo assessment of nirmatrelvir penetration into CSF, central nervous system cells, tissues, and peripheral blood mononuclear cells. · full record | OpenQuestion